Article
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Apr 2007
Cahill Daniel P, Levine Kymberly K, Betensky Rebecca A, Codd Patrick J, Romany Candice A, Reavie Linsey B, Batchelor Tracy T, Futreal P Andrew, Stratton Michael R, Curry William T, Iafrate A John, Louis David N
Abstract excerpt
PURPOSE: Glioblastomas are treated by surgical resection followed by radiotherapy [X-ray therapy (XRT)] and the alkylating chemotherapeutic agent temozolomide. Recently, inactivating mutations in the mismatch repair gene MSH6 were identified in two glioblastomas recurrent post-temozolomide. Because mismatch repair pathway inactivation is a known mediator of alkylator resistance in vitro, these findings suggested...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.